Evidence map›Paper›PMID 33514834›Full record

ArticleCommunications biology2021

The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo.

Briana Rackley, Chang-Soo Seong, Evan Kiely, Rebecca E Parker, Manali Rupji, Bhakti Dwivedi, John M Heddleston, William Giang, Neil Anthony, Teng-Leong Chew and 1 more

Open access · goldAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Briana Rackley *Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Chang-Soo Seong *Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Evan KielyDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6025-8519
Rebecca E ParkerDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3647-1616
Manali RupjiBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-0520-1624
Bhakti DwivediBioinformatics and Systems Biology Shared Resource, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
John M HeddlestonAdvanced Imaging Center, Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA.ORCID http://orcid.org/0000-0002-9289-4114
William GiangIntegrated Cellular Imaging Core, Emory University School of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-0829-259X
Neil AnthonyIntegrated Cellular Imaging Core, Emory University School of Medicine, Emory University, Atlanta, GA, USA.
Teng-Leong ChewAdvanced Imaging Center, Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA.ORCID http://orcid.org/0000-0002-3139-7560
Melissa Gilbert-RossDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. mmgilbe@emory.edu.ORCID http://orcid.org/0000-0002-1960-8302
Emory University · USHoward Hughes Medical Institute · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI SICA, GABRIEL LARKIN · 2019 to 2024
$10.1M
Drosophila Transgenic RNAi Resource ProjectR01GM084947 · NIGMS · HARVARD MEDICAL SCHOOL · PI PERRIMON, NORBERT · 2008 to 2019
$9.8M
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patientsR01CA194027 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.5M
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer S1R01CA201340 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.0M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA138292NCI NIH HHS P50 CA217691NCI NIH HHS R01 CA194027NCI NIH HHS R01 CA201340NIGMS NIH HHS R01 GM084947
6 · The paper itself

Abstract

The genetic and metabolic heterogeneity of RAS-driven cancers has confounded therapeutic strategies in the clinic. To address this, rapid and genetically tractable animal models are needed that recapitulate the heterogeneity of RAS-driven cancers in vivo. Here, we generate a Drosophila melanogaster model of Ras/Lkb1 mutant carcinoma. We show that low-level expression of oncogenic Ras (Ras

Indexed as

Genes, rasMutationAdenocarcinoma of LungAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsAnimals, Genetically ModifiedCalcium-Calmodulin-Dependent Protein KinasesCell DeathCell MovementDatabases, GeneticDrosophila melanogasterDrosophila ProteinsEnzyme ActivationGenetic Predisposition to DiseaseHumansAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesCalcium-Calmodulin-Dependent Protein KinasesDrosophila ProteinsKRAS protein, humanLKB1 protein, DrosophilaProtein KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STK11 protein, human

Identifiers

PMID33514834
PMCPMC7846793
OpenAlexW3122739245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.